MX2022002589A - Inhibidores de complemento para usarse en el tratamiento de pacientes con hemoglobinuria paroxistica nocturna. - Google Patents

Inhibidores de complemento para usarse en el tratamiento de pacientes con hemoglobinuria paroxistica nocturna.

Info

Publication number
MX2022002589A
MX2022002589A MX2022002589A MX2022002589A MX2022002589A MX 2022002589 A MX2022002589 A MX 2022002589A MX 2022002589 A MX2022002589 A MX 2022002589A MX 2022002589 A MX2022002589 A MX 2022002589A MX 2022002589 A MX2022002589 A MX 2022002589A
Authority
MX
Mexico
Prior art keywords
eculizumab
pnh
patients
paroxysmal nocturnal
nocturnal hemoglobinuria
Prior art date
Application number
MX2022002589A
Other languages
English (en)
Inventor
Leonard Bell
Russell P Rother
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38222520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022002589(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2022002589A publication Critical patent/MX2022002589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

El eculizumab, un anticuerpo monoclonal humanizado contra C5 que inhibe la activación del complemento terminal, mostró actividad en una prueba abierta preliminar de 12 semanas en una pequeña cohorte de pacientes con hemoglobinuria paroxística nocturna (PNH). El presente estudio examinó si la terapia crónica con eculizumab podía reducir la hemólisis intravascular, estabilizar los niveles de hemoglobina, reducir los requisitos de transfusión, y mejorar la calidad de vida en una prueba doble ciega, aleatoria, controlada con placebo, global multi-centro de fase III. Se ha encontrado que el eculizumab estabilizó los niveles de hemoglobina, disminuyó la necesidad de transfusiones y mejoró la calidad de vida en pacientes con PNH por medio de hemólisis intravascular reducida. El tratamiento crónico con eculizumab parece ser una terapia segura y efectiva para la PNH.
MX2022002589A 2006-03-15 2008-09-12 Inhibidores de complemento para usarse en el tratamiento de pacientes con hemoglobinuria paroxistica nocturna. MX2022002589A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78307006P 2006-03-15 2006-03-15

Publications (1)

Publication Number Publication Date
MX2022002589A true MX2022002589A (es) 2023-01-05

Family

ID=38222520

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2008011735A MX340784B (es) 2006-03-15 2007-03-15 Inhibidores de complemento para usarse en el tratamiento de pacientes con hemoglobinuria paroxística nocturna.
MX2022002589A MX2022002589A (es) 2006-03-15 2008-09-12 Inhibidores de complemento para usarse en el tratamiento de pacientes con hemoglobinuria paroxistica nocturna.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2008011735A MX340784B (es) 2006-03-15 2007-03-15 Inhibidores de complemento para usarse en el tratamiento de pacientes con hemoglobinuria paroxística nocturna.

Country Status (17)

Country Link
US (8) US20090220508A1 (es)
EP (5) EP4316465A3 (es)
JP (8) JP2009530299A (es)
KR (2) KR20140057635A (es)
AU (1) AU2007225044C1 (es)
BR (2) BR122017024057B8 (es)
CA (2) CA2645810C (es)
DK (1) DK2359834T5 (es)
ES (2) ES2965283T1 (es)
HK (1) HK1161119A1 (es)
HU (1) HUE030105T2 (es)
IL (4) IL302157A (es)
MX (2) MX340784B (es)
PL (1) PL2359834T3 (es)
PT (1) PT2359834T (es)
SI (1) SI2359834T1 (es)
WO (1) WO2007106585A1 (es)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1817340B1 (en) 2004-11-12 2012-05-16 Xencor, Inc. Fc variants with altered binding to fcrn
EP4316465A3 (en) 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
LT2808343T (lt) * 2007-12-26 2019-09-10 Xencor Inc. Fc variantai su pakitusiu prisijungimu prie fcrn
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
CA2732782C (en) 2008-08-05 2019-02-26 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
CA3035432A1 (en) * 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
ES2625470T3 (es) * 2009-11-09 2017-07-19 Alexion Pharmaceuticals, Inc.. Reactivos y métodos para detectar glóbulos blancos asociados a HPN de tipo II y su identificación como factores de riesgo para trastornos trombóticos
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP3330288A1 (en) 2011-12-21 2018-06-06 Novartis AG Compositions and methods for antibodies targeting factor p
HUE041996T2 (hu) * 2012-02-20 2019-07-29 Swedish Orphan Biovitrum Ab Publ A C5 humán komplementhez kötõdõ polipeptidek
WO2013137912A2 (en) * 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
EA038918B1 (ru) 2013-03-15 2021-11-09 Зинджения, Инк. Пептид, связывающий рецептор эпидермального фактора роста, мультиспецифические комплексы, содержащие пептид и антитела, и их применение
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
CN116987154A (zh) 2013-08-28 2023-11-03 阿菲博迪公司 具有突变的支架的结合多肽
BR122023020080A2 (pt) 2013-08-28 2023-12-26 Swedish Orphan Biovitrum Ab (Publ) Ligação de polipeptídeos estáveis ao c5 do complemento humano
WO2015054569A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
PL3154561T3 (pl) 2014-06-12 2019-12-31 Ra Pharmaceuticals, Inc. Modulowanie aktywności dopełniacza
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
AU2015324111B2 (en) 2014-09-29 2021-04-01 Chemocentryx, Inc. Processes and intermediates in the preparation of C5aR antagonists
EP3207058A1 (en) * 2014-10-15 2017-08-23 Alexion Pharmaceuticals, Inc. Methods of culturing a cell
JP6479974B2 (ja) 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
JP6948942B2 (ja) 2014-10-15 2021-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用
EP3699198A1 (en) 2014-11-17 2020-08-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
TW201809008A (zh) 2014-12-19 2018-03-16 日商中外製藥股份有限公司 抗ｃ５抗體及使用方法
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
JP6640229B2 (ja) 2015-01-28 2020-02-05 ラ ファーマシューティカルズ インコーポレイテッドＲａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体活性の変調剤
WO2016154290A1 (en) 2015-03-23 2016-09-29 Alexion Pharmaceuticals, Inc. Virus filtration
EP3277725B1 (en) 2015-03-30 2020-11-25 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
JP6944375B2 (ja) * 2015-03-31 2021-10-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
EP3307318A4 (en) 2015-06-09 2019-01-16 Children's Hospital Medical Center DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR
EP3307771A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
EP3313437A1 (en) * 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3341411A1 (en) 2015-08-28 2018-07-04 Alector LLC Anti-siglec-7 antibodies and methods of use thereof
US20170073399A1 (en) 2015-09-11 2017-03-16 Alexion Pharmaceuticals, Inc. Recombinant glycosylated eculizumab and eculizumab variants
EP3359569A2 (en) 2015-10-06 2018-08-15 Alector LLC Anti-trem2 antibodies and methods of use thereof
US11203634B2 (en) 2015-10-07 2021-12-21 Alexion Pharmaceuticals, Inc. Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
AU2016343987B2 (en) 2015-10-29 2023-11-23 Alector Llc Anti-Siglec-9 antibodies and methods of use thereof
ES2941640T3 (es) * 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
BR112018014222A2 (pt) * 2016-01-14 2018-12-11 Chemocentryx, Inc. método de tratamento da glomerulopatia c3
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
IL309975A (en) 2016-06-14 2024-03-01 Regeneron Pharma Antibodies against C5 and their uses
WO2018025982A1 (ja) 2016-08-05 2018-02-08 中外製薬株式会社 Ｉｌ－８関連疾患の治療用又は予防用組成物
EP3529618B1 (en) 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
AU2017370692A1 (en) 2016-12-07 2019-06-06 Ra Pharmaceuticals, Inc. Modulators of complement activity
EP3554543A4 (en) * 2016-12-16 2020-09-02 Samsung Bioepis Co., Ltd. STABLE AQUEOUS COMPOSITION OF ANTI-C5 ANTIBODIES
SG11201801401UA (en) 2017-01-31 2018-09-27 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3625258A1 (en) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
EP3630819B1 (en) 2017-05-22 2023-10-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients
AU2018306612C1 (en) 2017-07-27 2023-11-09 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations
WO2019028284A1 (en) * 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
HUE062436T2 (hu) 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
AU2018310985A1 (en) 2017-08-03 2019-11-07 Alector Llc Anti-CD33 antibodies and methods of use thereof
CA3082406A1 (en) 2017-11-14 2019-05-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
RU2020117578A (ru) * 2017-12-04 2022-01-14 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
CA3083113A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
EP3732193A1 (en) 2017-12-29 2020-11-04 Alector LLC Anti-tmem106b antibodies and methods of use thereof
CN111971301A (zh) 2018-01-31 2020-11-20 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
AR115418A1 (es) 2018-05-25 2021-01-13 Alector Llc ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
AU2019282778A1 (en) 2018-06-08 2020-12-10 Alector Llc Anti-Siglec-7 antibodies and methods of use thereof
US20210238268A1 (en) * 2018-06-19 2021-08-05 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
SG11202010990TA (en) 2018-06-29 2020-12-30 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso
BR112021001451A2 (pt) 2018-07-27 2021-04-27 Alector Llc anticorpos monoclonais anti-siglec-5 isolados, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, composição farmacêutica e métodos para induzir ou promover a sobrevida, para diminuir a atividade, para diminuir os níveis celulares, para induzir a produção de espécies reativas, para induzir a formação de neutrophil extracellular trap (net), para induzir a ativação de neutrófilos, para atenuar um ou mais neutrófilos imunossuprimidos e para aumentar a atividade de fagocitose
KR20200033348A (ko) 2018-08-01 2020-03-27 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
SG11202101552SA (en) 2018-08-31 2021-03-30 Alector Llc Anti-cd33 antibodies and methods of use thereof
WO2020047389A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
KR20210093855A (ko) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 보체 인자 d 억제제의 형태체 형태
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
US20200392229A1 (en) 2019-06-11 2020-12-17 Alector Llc Methods of use of anti-sortilin antibodies
US11667699B2 (en) 2019-07-31 2023-06-06 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
CN114466660A (zh) 2019-07-31 2022-05-10 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
KR20240033090A (ko) 2019-07-31 2024-03-12 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
WO2021026160A1 (en) 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
MX2022006073A (es) 2019-12-05 2022-08-04 Alector Llc Metodos para utilizar anticuerpos anti-trem2.
JP2023506014A (ja) 2019-12-12 2023-02-14 アレクトル エルエルシー 抗ｃｄ３３抗体の使用方法
CR20220329A (es) 2019-12-13 2022-11-23 Alector Llc Anticuerpos anti–mertk y metodos de uso de los mismos
US20230159637A1 (en) 2020-02-24 2023-05-25 Alector Llc Methods of use of anti-trem2 antibodies
EP4126937A1 (en) 2020-03-31 2023-02-08 Alector LLC Anti-mertk antibodies and methods of use thereof
KR20230005848A (ko) 2020-04-03 2023-01-10 알렉터 엘엘씨 항-trem2 항체의 사용 방법
CN116406287A (zh) 2020-04-16 2023-07-07 巴黎公共医疗救助机构 治疗由病毒引起的补体介导的障碍的方法
KR20230009431A (ko) 2020-05-12 2023-01-17 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨증의 치료를 위한 보체 인자 d 저해제를 단독으로 또는 항-c5 항체와 조합한 용도
AU2021392039A1 (en) 2020-12-02 2023-06-29 Alector Llc Methods of use of anti-sortilin antibodies
CN116981696A (zh) 2021-03-18 2023-10-31 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
JP2024511610A (ja) 2021-03-23 2024-03-14 アレクトル エルエルシー コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
EP4355783A1 (en) 2021-06-16 2024-04-24 Alector LLC Monovalent anti-mertk antibodies and methods of use thereof
CN117642426A (zh) 2021-06-16 2024-03-01 艾莱克特有限责任公司 双特异性抗MerTK和抗PDL1抗体及其使用方法
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
WO2024015830A1 (en) 2022-07-12 2024-01-18 Cytomx Therapeutics, Inc. Epcam immunoconjugates and uses thereof
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5705732A (en) 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
WO1992010205A1 (en) 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US6025165A (en) 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP3971797B2 (ja) 1994-09-23 2007-09-05 アレクション・ファーマシューティカルズ・インク 炎症性関節疾患の治療方法
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2001058526A2 (en) 2000-02-10 2001-08-16 Alexion Pharmaceuticals, Inc. Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
EP1325033B1 (en) 2000-10-10 2009-11-25 Genentech, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ATE414720T1 (de) * 2000-12-05 2008-12-15 Alexion Pharma Inc Rationell entworfene antikörper
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003009803A2 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
WO2003015819A1 (en) 2001-08-17 2003-02-27 Tanox, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
US20050221382A1 (en) * 2002-03-18 2005-10-06 Rother Russell P Stratification of patient populations having or suspected of having rheumatoid arthritis
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
AU2003265361A1 (en) 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
DK1553975T3 (da) 2002-09-27 2012-05-07 Xencor Inc Optimerede Fc-varianter og fremgangsmåder til generering heraf.
KR101348472B1 (ko) 2002-10-17 2014-01-07 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
WO2004056104A1 (en) 2002-12-16 2004-07-01 Koninklijke Philips Electronics N.V. Personal video recorder method and user interface
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
JP2006516636A (ja) 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド 抗インテグリンαｖβ３抗体製剤及びその用途
CA2515444C (en) 2003-02-10 2014-04-01 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
WO2004096833A2 (en) * 2003-04-25 2004-11-11 Immunex Corporation Inducers of recombinant protein expression
AU2004257142A1 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
JP2006526414A (ja) 2003-06-02 2006-11-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 脱免疫化抗ｃｄ３抗体
US20050027166A1 (en) 2003-06-17 2005-02-03 Shinya Matsumoto Endoscope system for fluorescent observation
AT412877B (de) 2003-07-01 2005-08-25 Miba Gleitlager Gmbh Schichtwerkstoff
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
ES2376556T3 (es) 2004-03-24 2012-03-14 Abbott Biotherapeutics Corp. Utilización de la anticuerpos anti-alfa5beta1 para inhibir la proliferación de las células cancerosas.
CA2566716C (en) 2004-05-14 2014-12-23 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
DK2287195T3 (da) 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
WO2006012415A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
WO2006127517A2 (en) 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
WO2007002571A2 (en) 2005-06-23 2007-01-04 Alexion Pharmaceuticals, Inc. Use of an anti c5 complement antibody to treat patients with sickle cell disease
AU2006265936A1 (en) 2005-07-01 2007-01-11 Medimmune, Llc An integrated approach for generating multidomain protein therapeutics
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
SG171578A1 (en) 2006-03-02 2011-06-29 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
EP4316465A3 (en) 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
AU2006343402A1 (en) 2006-05-01 2007-11-15 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
NZ575018A (en) 2006-09-05 2012-04-27 Alexion Pharma Inc Compositions for the treatment of antibody mediated neuropathies
CA2814155C (en) 2010-06-11 2019-10-22 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody

Also Published As

Publication number Publication date
US10703809B1 (en) 2020-07-07
BRPI0708909B1 (pt) 2021-02-09
IL194041A0 (en) 2011-08-01
IL258548A (en) 2018-05-31
IL252260A0 (en) 2017-07-31
US20090220508A1 (en) 2009-09-03
CA2645810A1 (en) 2007-09-20
CA2645810C (en) 2018-12-11
EP4316465A3 (en) 2024-04-24
SI2359834T1 (sl) 2017-02-28
EP3124029A1 (en) 2017-02-01
JP2016034978A (ja) 2016-03-17
CA3022097C (en) 2020-10-27
JP2017082017A (ja) 2017-05-18
US20160376355A1 (en) 2016-12-29
AU2007225044A1 (en) 2007-09-20
ES2965283T1 (es) 2024-04-11
EP2001490A1 (en) 2008-12-17
US20170349652A1 (en) 2017-12-07
US10590189B2 (en) 2020-03-17
IL252260B (en) 2018-04-30
JP2014015484A (ja) 2014-01-30
US20200392216A1 (en) 2020-12-17
IL302157A (en) 2023-06-01
MX340784B (es) 2016-07-26
US9725504B2 (en) 2017-08-08
AU2007225044B2 (en) 2013-03-07
CA3022097A1 (en) 2007-09-20
KR20140057635A (ko) 2014-05-13
AU2007225044C1 (en) 2018-03-29
US20200199211A1 (en) 2020-06-25
US20170015741A1 (en) 2017-01-19
BRPI0708909B8 (pt) 2021-05-25
JP6224059B2 (ja) 2017-11-01
WO2007106585A1 (en) 2007-09-20
US9732149B2 (en) 2017-08-15
EP4316465A2 (en) 2024-02-07
JP2009530299A (ja) 2009-08-27
EP2359834A1 (en) 2011-08-24
DK2359834T5 (en) 2017-02-06
PL2359834T3 (pl) 2017-09-29
EP2359834B1 (en) 2016-11-09
PT2359834T (pt) 2016-12-23
BR122017024057B8 (pt) 2021-05-25
EP3167888A1 (en) 2017-05-17
US9718880B2 (en) 2017-08-01
BRPI0708909A2 (pt) 2011-06-14
JP2020002176A (ja) 2020-01-09
US20120237515A1 (en) 2012-09-20
BR122017024057B1 (pt) 2021-02-17
JP2018165277A (ja) 2018-10-25
KR20080110800A (ko) 2008-12-19
US20160244516A1 (en) 2016-08-25
JP2021073319A (ja) 2021-05-13
HUE030105T2 (en) 2017-04-28
MX2008011735A (es) 2009-02-06
IL194041A (en) 2017-10-31
HK1161119A1 (zh) 2012-08-24
JP2023026536A (ja) 2023-02-24
DK2359834T3 (en) 2017-01-16
ES2612118T3 (es) 2017-05-12

Similar Documents

Publication Publication Date Title
MX340784B (es) Inhibidores de complemento para usarse en el tratamiento de pacientes con hemoglobinuria paroxística nocturna.
Na et al. Effects of intravenous iron combined with low‐dose recombinant human erythropoietin on transfusion requirements in iron‐deficient patients undergoing bilateral total knee replacement arthroplasty (CME)
MX2012005151A (es) Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
IN2012DN00827A (es)
MX355482B (es) Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia.
WO2004075838A3 (en) Method and compositions for the treatment of meconium aspiration syndrome
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
WO2008034076A3 (en) Cyclophosphamide in combination with immune therapeutics
WO2007053807A3 (en) Calcitriol for treating intraocular diseases associated with angiogenesis
WO2006083710A3 (en) Use of 5-ht4 agonist for treating delayed gastric emptying which may be induced by a proton pump inhibitor
WO2003105774A3 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS THEREOF
Villamaria et al. Hydrogen sulfide mitigates reperfusion injury in a porcine model of vascularized composite autotransplantation
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
Nautiyal et al. Comparison of candesartan and angiotensin-(1-7) combination to mito-TEMPO treatment for normalizing blood pressure and sympathovagal balance in (mREN2) 27 rats
Chen et al. Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease
Elliott The efficacy and safety of telmisartan compared to atenolol and placebo in patients with hypertension
TN2011000206A1 (en) Compositions and methods of use soluble thrombomodulin variants
Zhang et al. The Role of Peripheral Extracellular Signal-regulated Protein Kinase (ERK) in Experimental Arthritic Pain in Rats
WO2007011960A3 (en) Methods and agents to treat autoimmune diseases
SI1948216T1 (sl) Zdravljenje akutne ledviäśne odpovedi s topnim trombomodulinom
Aalbers Saxagliptin efficacy and safety in special patient groups (the elderly and those with renal impairment): drug trends
Bauer Lack of efficacy in anaphylaxis: case report
Xiao et al. Evaluation of efficacy and safety of bevacizumab combined with chemotherapy for Chinese patients with advanced non-small cell lung cancer
de Champlain et al. EFFECTS OF TELMISARTAN, RAMIPRIL AND AMLODIPINE ON ORCADIAN BLOOD PRESSURE, HEART RATE, NOREPINEPHRINE, RENIN AND ALDOSTERONE CYCLES IN ESSENTIAL HYPERTENSIVE PATIENTS: OP 029